dyslipidemia
Conditions
Interventions
Rosuvastatin 2.5 mg is administered to all participating patients. When LDL-C does not lower to desired level 1 month after administration, Rosuvastatin is increased to 5.0 mg. We continue administrat
Sponsors
The University of Tokyo Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: This study is targeting to invite about 100 patients with high-LDL cholesterol, who are recommended to administer the statin according to Japanese guideline of dyslipidemia.
Exclusion criteria
Exclusion criteria: 1) Secondary dyslipidemia, due to hypothyroidism, nephrotic syndrome, Cushing syndrome, and so on. 2) Familial hypercholesterolemia 3) Fasting TG is over 500 mg/dl 4) Renal dysfunction (Creatinin 2.0 mg/dl, or blood ure nitrogen 25 mg/dl) 5) Liver dysfunction (transaminase is more than three times the upper limit of normal) 6) Higher serum level of Creatin kinase (more than three times the upper limit of normal) 7) Pregnant women and women who are suspected to get pregnant 8) Patients who are taking drugs which is contraindication in combination with statin such as Cyclosporine or Fibrates 9) Patients who have a history of adverse effect of statins. 10) Patients who are judged ineligible
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| All patients are devided into "more increase in TG" group and "less increase in TG" group, according to the median of the sum total of POST PRANDIAL TG ELEVATION ((TG in 4 hours minus fasting)+ (TG in 2 hours minus fasting)), before administration of statin. Primary outcome of this study is that there will be a significant difference of POST PRALDIAL TG ELEVATION and small, dense-LDL levels at 3 months after administration of statin between two groups. We use Student-T test as statistical analysis. | — |
Countries
Japan
Contacts
Public ContactHironori Muraoka, MD.
The University of Tokyo Hospital Cardiology
Outcome results
None listed